Plain-English translation of NCT06993038 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
When you come to the emergency department with a sudden, rapid heartbeat (called supraventricular tachycardia or SVT), doctors have two main medications they can give you to restore a normal heart rate: and . This small pilot study is asking which of these two treatments feels better to patients and works well for stopping the racing heartbeat.
Both medications can effectively stop a racing heartbeat, but doctors and patients don't have clear information about which one feels better or is easier to tolerate. This study will help doctors understand your experience with these treatments so they can make better decisions about which medication to use.
You likely qualify if…
You likely don't qualify if…
You would receive one of the two medications through an IV in the emergency department to stop your racing heartbeat. After the medication takes effect and your heart rate returns to normal, you would be asked questions about your experience with the treatment—such as how you felt, any side effects you noticed, and your impression of the medication. The entire process would happen during your emergency department visit.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Anne E. Zepeski
Enrollment target
~20 participants
Started
August 2025
Primary completion
July 2027
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anne Zepeski, PharmD
University of Iowa
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.